SecBot SecBot
8-K ·Filed Mar 4, 2026

VIR

Vir Biotechnology, Inc.
NEUTRAL
Impact 3/10
Horizonmonths Processed8mo ago SEC0001193125-26-091447
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

Monitor for any future disclosures regarding changes in executive compensation or strategic direction that may result from the expanded role. No trading action warranted based on this filing alone.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$9.10
T+0 close · Mar 4, 2026 · via day close
Latest settled
−0.77%
T+60 · $9.03
Vs SPY
−12.07%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 5 $9.10entry
  2. T+1 · 9mo ago +4.95%α +6.26% · $9.55
  3. T+5 · 8mo ago +4.18%α +6.41% · $9.48
  4. T+20 · 8mo ago −0.44%α +3.35% · $9.06
  5. T+60 · 6mo ago −0.77%α −12.07% · $9.03
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vir Biotechnology appointed CEO Marianne De Backer to the additional role of President. This is an internal leadership expansion with no immediate financial impact or executive departure.

Key Facts

  • Marianne De Backer, current CEO and principal executive officer, was appointed to the additional role of President on March 4, 2026
  • No executive departures were reported
  • No compensation details were disclosed in the filing
  • The appointment reflects a consolidation of leadership roles under the existing CEO

Financial Impact

No immediate financial impact disclosed

executive leadershipgovernance

Risk Factors

  • Potential concentration of power in a single executive without checks and balances
  • Lack of disclosed succession planning if De Backer holds both CEO and President roles

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-091447
Document: 0001193125-26-091447-index-headers.html0001193125-26-091447
Document: 0001193125-26-091447-index.html0001193125-26-091447
Document: 0001193125-26-091447.txt0001193125-26-091447

Track record

36 reports on VIR

Performance horizon

4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +29.79% at T+5 after the Nov 6, 2026 report. 5 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today 424B5 Bearish 5/10 Entry price pending
  2. Nov 13, 20263d ago 8-K Bearish 5/10 Entry $9.92 Now $9.58 +3.43% settles Nov 23
  3. Nov 12, 20264d ago 424B5 Bearish 5/10 Entry $9.96 Now $9.58 +3.82% settles Nov 20
  4. Nov 12, 20264d ago S-3ASR Neutral 3/10 Entry $9.96 Now $9.58 −3.82% settles Nov 20
  5. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $13.15 Now $9.58 −27.15% settles Nov 17
  6. Nov 9, 20267d ago 8-K Bullish 6/10 Entry $13.65 to $9.58 Now $9.58 −29.79% ▼ −29.79% −28.10% vs SPY
  7. Nov 6, 202610d ago SC 13D/A Bearish 5/10 Entry $13.65 to $9.58 Now $9.58 +29.79% ▲ +29.79% +28.10% vs SPY
  8. Nov 4, 202612d ago 8-K Neutral 5/10 Entry $11.02 to $12.12 Now $9.58 −13.07% ▲ +9.98% +6.69% vs SPY
  9. Nov 3, 202613d ago 144 Neutral 2/10 Entry $11.22 to $13.15 Now $9.58 −14.62% ▲ +17.20% +17.79% vs SPY
  10. Nov 2, 202614d ago 144 Neutral 1/10 Entry $11.00 to $13.65 Now $9.58 −12.91% ▲ +24.05% +23.97% vs SPY
Showing 10 of 36

US Market Status

Market Closed · Opens Wed (9h 33m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 4, 2026